If the U.S. government wants to rein in healthcare spending, one of the biggest cost-saving measures should be ensuring that pharmaceutical companies don’t profit from drugs developed using taxpayer money without fairly compensating the public.
The pharmaceutical industry often justifies its sky-high drug prices by pointing to the billions spent on research and development (R&D). However, they fail to mention how much of that R&D is funded by the federal government through agencies like the National Institutes of Health (NIH). Taxpayer-funded research has been key in developing groundbreaking treatments, from cancer drugs to COVID-19 vaccines. Yet, once these drugs show promise, pharma companies swoop in secure patents, and charge exorbitant prices—without repaying the public investment that made their success possible.
The Public Foots the Bill, Pharma Takes the Profits
A 2019 study published in JAMA found that every one of the 210 new drugs approved by the FDA between 2010 and 2016 relied on NIH-supported research. Yet, when these drugs hit the market, patients and the federal government are forced to pay sky-high prices while pharma companies rake in billions.
Take the cancer drug Xtandi, for example. The U.S. Department of Veterans Affairs and NIH funded its early-stage development, yet it costs more American patients than other countries. Despite the government’s role in its creation, the price is dictated entirely by the pharmaceutical company that holds its patent.
Then there’s the COVID-19 vaccine, a historic example of public funding paving the way for pharmaceutical windfalls. The U.S. government invested billions in research, development, and distribution, yet Pfizer and Moderna reaped record-breaking profits once the vaccines hit the market.
March-In Rights: A Solution That’s Been Ignored
Under the 1980 Bayh-Dole Act, the federal government has what is known as march-in rights, which allow it to step in and take control of a patent when a drug that benefited from public funding is being priced unfairly or not made widely available. But despite the clear intent of this law, these rights have never been exercised—not even when Americans pay many times more for life-saving drugs than patients in other countries.
Pharma companies have aggressively lobbied against using march-in rights, arguing that such action would stifle innovation. But that’s a weak excuse, considering that much of early-stage innovation comes from publicly funded research. The reality is that pharma’s business model depends on leveraging taxpayer-funded discoveries and then charging those same taxpayers sky-high prices.
What Needs to Change?
If the government is serious about cutting healthcare costs, it must take a hard stance on taxpayer-funded drug development. Here’s how:
- Enforce March-In Rights—If a drug was developed with significant federal funding, the government should have the right to ensure it’s priced fairly. If pharmaceutical companies refuse, the government should license the patent to another manufacturer or produce the drug.
- Demand Higher Royalties—When a pharmaceutical company licenses a drug developed with public funding, the government should demand higher royalty payments, ensuring a return on investment for taxpayers.
- Attach Pricing Conditions to Publicly Funded Research – Any company benefiting from government-funded research should be required to offer fair pricing or face penalties.
- Increase Oversight on Pharma Patents – Pharma companies routinely extend patents on taxpayer-funded drugs using tactics like “evergreening” (making minor changes to extend exclusivity). Stricter oversight could prevent this abuse.
The U.S. government spends billions annually on healthcare, including covering prescription drugs through Medicare and Medicaid. By allowing pharma companies to take publicly funded research and turn it into high-priced monopolies, we’re essentially paying for the same drugs twice—first through taxpayer-funded study and then again through sky-high prices.
If policymakers are truly committed to lowering drug prices and reducing federal spending, the solution is simple: make pharmaceutical companies pay their fair share for the drugs they profit from. The era of pharmaceutical companies poaching taxpayer-funded drugs without consequences must end.

